CLIA Adiponectin
The chemiluminescence assay is intended for the diagnosis of metabolic disorders using adiponectin determination in human serum in the general population.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
- increased risk of type 2 diabetes,
- endothelial dysfunction and accelerated atherogenesis,
- occurrence of hypertension,
- left ventricular hypertrophy and cardiometabolic mortality.
- A low Adpn/Lep ratio is associated with leptin resistance, insulin resistance, and an increased risk of metabolic syndrome.
- The Adpn/Lep ratio can identify metabolic risk earlier than conventional clinical markers such as fasting glucose or triglycerides.
- In pediatric populations, it enables early detection of emerging obesity and related metabolic disturbances.
- It supports the personalization of preventive and therapeutic strategies based on an individual’s metabolic profile.
Description
Adiponectin and leptin are among the most important adipokines produced by adipose tissue. These hormones not only act as signaling molecules in energy metabolism but also play a key role in regulating inflammatory processes, insulin sensitivity, and the development of cardiometabolic diseases. Their circulating concentrations and mutual ratio serve as valuable biomarkers for the early detection of metabolic dysfunction and the risk of developing type 2 diabetes or cardiovascular disease.
Adiponectin – a protective adipokine with antidiabetic and anti-inflammatory effects Adiponectin is a hormone produced by adipose tissue that protects blood vessels and helps reduce inflammation. Unlike leptin, its circulating levels decrease as visceral fat increases. Low adiponectin levels are associated with:
Adiponectin promotes fatty acid oxidation in the liver and muscles, reduces the production of TNF-α and other pro-inflammatory mediators, and improves insulin sensitivity. For these reasons, it is considered one of the strongest protective factors for metabolic health.
Adiponectin-to-leptin ratio (Adpn/Lep) – a comprehensive marker of adipose tissue function The Adpn/Lep ratio has emerged as a sensitive indicator of adipose tissue dysfunction and metabolic imbalance. It reflects the balance between the protective and risk-associated effects of adipokines.
Given their role in the pathogenesis of insulin resistance and atherosclerosis, adiponectin and leptin are increasingly recommended as complementary biomarkers for patients with obesity, prediabetes, and cardiometabolic risk.
Technical data
- Assay time: 15 min
- Assay stability: 30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
- Sample matrix: Serum
- Sample volume: 13 μL
- Sample stability: 7 days at 2-8 °C, 24 months at -20 °C
- Measuring range: 12.5 – 800 ng/ml
- Complementary products: Anchor® Tips, Stackable Cuvette, KleeYa Trigger Pack, KleeYa Wash buffer
- Note: The kits are CE-IVD certified and intended for professional use.
Specifications
- Catalog Number: CL-ADP050
- Size: 50 tests
- Regulatory status: CE IVD
- Clinical topic: Diabetes & Metabolism Disorders
- Diagnostic panel: Metabolic Syndrome Panel
- Producer: TestLine Clinical Diagnostics s.r.o.
References
- Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol. 2016 Apr;8(2):93-100. doi: 10.1093/jmcb/mjw011. Epub 2016 Mar 18. PMID: 26993047; PMCID: PMC4816148.
- Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A, Daniele A. New insight into adiponectin role in obesity and obesity- related diseases. Biomed Res Int. 2014;2014:658913. doi: 10.1155/2014/658913. Epub 2014 Jul 7. PMID: 25110685; PMCID: PMC4109424.
- Otto C, Otto B, Göke B, Pfeiffer AF, Lehrke M, Vogeser M, Spranger J, Parhofer KG. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest. 2006 Mar;29(3):231-6. doi: 10.1007/BF03345545. PMID: 16682836.
- Moon HU, Ha KH, Han SJ, Kim HJ, Kim DJ. The Association of Adiponectin and Visceral Fat with Insulin Resistance and β-Cell Dysfunction. J Korean Med Sci. 2018 Dec 26;34(1):e7. doi: 10.3346/jkms.2019.34.e7. PMID: 30618514; PMCID: PMC6318440.
- Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009 Jul 8;302(2):179-88. doi: 10.1001/jama.2009.976. PMID: 19584347.
- Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Galatius S, Jeppesen J, Mogelvang R. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol. 2015 Mar;22(3):276-83. doi: 10.1177/2047487313514894. Epub 2013 Nov 21. PMID: 24265290.
- Kashiwagi R, Yamada Y, Ito Y, Mitsui Y, Sakaue T, Iwamoto R, Saisho K, Tamba S, Yamamoto K, Watanabe T, Fujimoto T, Iwahashi H, Matsuzawa Y. Increase in Adiponectin Level Prevents the Development of Type 2 Diabetes in Japanese Men With Low Adiponectin Levels. J Endocr Soc. 2018 Jun 14;2(7):753-764. doi: 10.1210/js.2018-00033. PMID: 29978152; PMCID: PMC6030829.
- Baden MY, Yamada Y, Obata Y, Hosakawa Y, Saisho K, Tamba S, Yamamoto K, Umeda M, Furubayashi A, Tsukamoto Y, Matsuzawa Y. Serum adiponectin level is not only decreased in metabolic syndrome but also in borderline metabolic abnormalities. Nutr Diabetes. 2011 Oct 10;1(10):e18. doi: 10.1038/nutd.2011.13. PMID: 23455020; PMCID: PMC3302140.
- Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012 Feb;165(3):574-90. doi: 10.1111/j.1476-5381.2011.01395.x. PMID: 21457225; PMCID: PMC3315032.
- Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012 Aug;33(4):547-94. doi: 10.1210/er.2011-1015. Epub 2012 Apr 30. PMID: 22547160; PMCID: PMC3410224.
- Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018 Jan 2;7(1):57-62. doi: 10.1080/21623945.2017.1402151. Epub 2017 Dec 5. PMID: 29205099; PMCID: PMC5915018.
- Behrouz V, Jazayeri S, Aryaeian N, Zahedi MJ, Hosseini F. Effects of Probiotic and Prebiotic Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Middle East J Dig Dis. 2017 Jul;9(3):150-157. doi: 10.15171/mejdd.2017.66. PMID: 28894517; PMCID: PMC5585907.
- Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO, Möhlig M, Pfeiffer AF, Spranger J. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes. 2005 Sep;54(9):2712-9. doi: 10.2337/diabetes.54.9.2712. PMID: 16123361.
- van Gemert WA, Monninkhof EM, May AM, Elias SG, van der Palen J, Veldhuis W, Stapper M, Stellato RK, Schuit JA, Peeters PH. Association between changes in fat distribution and biomarkers for breast cancer. Endocr Relat Cancer. 2017 Jun;24(6):297-305. doi: 10.1530/ERC-16-0490. Epub 2017 May 16. PMID: 28512158.
- Reagent Cartridge with specific reagents for the assay
- magnetic particles
- calibrators
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Safety information
Product brochure
Declaration of conformity
Frequently paired with this kit
Other assays and instruments lab teams add alongside the CLIA Adiponectin.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
